Tetrahydrocannabivarin (THCV) Cannabinoid Research

Tetrahydrocannabivarin (THCV) Research Dashboard

43

Primary Studies

12

Related Studies

55

Total Studies

Clinical Studies

0

Clinical Meta-analyses

4

Double-blind, placebo-controlled human trials

0

Clinical human trials

Pre-Clinical Studies

9

Meta-analyses/Reviews

11

Animal studies

18

Laboratory studies

Studies by Organ System

No data to display

Studies by Country of Researcher

No data to display

Top Conditions Related to THCV Studies

No data to display

Receptors Associated with THCV Studies

No data to display

There Is Clinical Evidence Using THCV for These Conditions:

Select New Cannabinoid

Filter Cannabinoid

43 PRIMARY STUDIES | 55 TOTAL STUDIES

Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents

Type of Study: Animal Study

Year of Pub: 2022

Identification of Chemotypic Markers in Three Chemotype Categories of Cannabis Using Secondary Metabolites Profiled in Inflorescences, Leaves, Stem Bark, and Roots

Type of Study: Laboratory Study

Year of Pub: 2021

Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels

Type of Study: Laboratory Study

Year of Pub: 2021

Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats

Type of Study: Animal Study

Year of Pub: 2021

The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice

Type of Study: Laboratory Study

Year of Pub: 2021

Development and Optimization of Supercritical Fluid Extraction Setup Leading to Quantification of 11 Cannabinoids Derived from Medicinal Cannabis

Type of Study: Laboratory Study

Year of Pub: 2021

Fast liquid chromatography-tandem mass spectrometry method for the simultaneous determination of phytocannabinoids in oily based preparations

Type of Study: Laboratory Study

Year of Pub: 2021

Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms

Type of Study: Laboratory Study

Year of Pub: 2021

Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target

Type of Study: Meta-analysis

Year of Pub: 2021

Identification and quantification of cannabinoids in postmortem fluids and tissues by liquid chromatography-tandem mass spectrometry

Type of Study: Laboratory Study

Year of Pub: 2021

An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models

Type of Study: Laboratory Study

Year of Pub: 2021

Screening and confirmation methods for the qualitative identification of nine phytocannabinoids in urine by LC-MS/MS

Type of Study: Laboratory Study

Year of Pub: 2021

The Cannabinoids Tetrahydrocannabinol, Cannabinol, Cannabidiol, Tetrahydrocannabivarin, and 11-nor-9-carboxy-∆9-THC in Hair

Type of Study: Laboratory Study

Year of Pub: 2021

Quantitation of Δ8-THC, Δ9-THC, Cannabidiol, and Ten Other Cannabinoids and Metabolites in Oral Fluid by HPLC-MS/MS

Type of Study: Laboratory Study

Year of Pub: 2021

Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

Type of Study: Meta-analysis

Year of Pub: 2021

Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro

Type of Study: Laboratory Study

Year of Pub: 2021

Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

Type of Study: Animal Study

Year of Pub: 2020

Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L

Type of Study: Laboratory Study

Year of Pub: 2020

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

Type of Study: Meta-analysis

Year of Pub: 2020

High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain

Type of Study: Animal Study

Year of Pub: 2020

Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath

Type of Study: Laboratory Study

Year of Pub: 2020

It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets

Type of Study: Meta-analysis

Year of Pub: 2020

Cannabinoids and Cannabinoid Receptors: The Story so Far

Type of Study: Meta-analysis

Year of Pub: 2020

Synthesis of the Major Mammalian Metabolites of THCV

Type of Study: Meta-analysis

Year of Pub: 2020

Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders

Type of Study: Meta-analysis

Year of Pub: 2019

Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence

Type of Study: Animal Study

Year of Pub: 2019

Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes

Type of Study: Laboratory Study

Year of Pub: 2019

Effects of non‐euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice

Type of Study: Laboratory Study

Year of Pub: 2018

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Type of Study: Double Blind Human Trial

Year of Pub: 2016

The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

Type of Study: Double Blind Human Trial

Year of Pub: 2016

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers

Type of Study: Double Blind Human Trial

Year of Pub: 2016

Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers

Type of Study: Double Blind Human Trial

Year of Pub: 2015

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

Type of Study: Meta-analysis

Year of Pub: 2015

The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects

Type of Study: Animal Study

Year of Pub: 2015

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

Type of Study: Animal Study

Year of Pub: 2013

Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats

Type of Study: Animal Study

Year of Pub: 2013

Δ8-Tetrahydrocannabivarin Prevents Hepatic Ischaemia/Reperfusion Injury by Decreasing Oxidative Stress and Inflammatory Responses Through Cannabinoid CB2 Receptors

Type of Study: Animal Study

Year of Pub: 2012

Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

Type of Study: Laboratory Study

Year of Pub: 2012

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease

Type of Study: Animal Study

Year of Pub: 2011

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

Type of Study: Meta-analysis

Year of Pub: 2009

The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum

Type of Study: Laboratory Study

Year of Pub: 2008

The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo

Type of Study: Animal Study

Year of Pub: 2007

12 RELATED STUDIES | 55 TOTAL STUDIES

Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

Type of Study: Meta-analysis

Year of Pub: 2022

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Type of Study: Laboratory Study

Year of Pub: 2021

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions

Type of Study: Laboratory Study

Year of Pub: 2021

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Type of Study: Laboratory Study

Year of Pub: 2020

Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets

Type of Study: Laboratory Study

Year of Pub: 2020

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Type of Study: Meta-analysis

Year of Pub: 2019

Future Aspects for Cannabinoids in Breast Cancer Therapy

Type of Study: Meta-analysis

Year of Pub: 2019

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients

Type of Study: Meta-analysis

Year of Pub: 2019

Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary

Type of Study: Meta-analysis

Year of Pub: 2019

Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome

Type of Study: Meta-analysis

Year of Pub: 2019

Molecular Targets of the Phytocannabinoids-A Complex Picture

Type of Study: Meta-analysis

Year of Pub: 2017

Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth In Vitro And In Vivo: Pro-apoptotic Effects And Underlying Mechanisms

Type of Study: Animal Study

Year of Pub: 2013

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Type of Study: Animal Study

Year of Pub: 2012

Overview - Tetrahydrocannabivarin (THCV)

Description of Tetrahydrocannabivarin (THCV)

Δ9-Tetrahydrocannabivarin (THCV) was discovered in 1971. [Δ(8) -THCV (is a synthetic analogue of the plant cannabinoid Δ(9) -THCV]. THCV belongs to the THC group but produces different effects than THC. A lot of attention is given THCV of late due to the observation that it may be able to produce therapeutic effects in obesity related diabetes especially in contrast to the failed approach with Rimonabant, the CB1 inverse agonist used to treat obesity but then pulled from market due to the potential increased of mood disorders.

Other Names:

Delta 9-Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV) Properties and Effects

THCV modulates lipid and sugar metabolism (i.e. reduces insulin sensitivity) and as such THCV may represent a novel therapeutic agent to induce glycemic control in patients with type 2 diabetes; antioxidant and neuroprotective [i.e. reduces symptoms in an animal model of Parkinson's disease (i.e. reduces L-DOPA-induced dyskinesia)]; antimicrobial (i.e. against MRSA); THCV inhibited some effects of THC (e.g. reduced THC associated increases in heart rate, decrease in THC associated psychoactivity) while increasing others i.e. significantly increased memory intrusions; THCV may induce dose dependent dysphoria (due to its antagonistic effects at CB1); Δ8 -THCV may have potential anti-nicotine effects.

Tetrahydrocannabivarin (THCV) Receptor Binding

Pooling five studies THCV has a reported Ki of 64.2 ± 14.14 nM (McPartland, Pertwee et. al. 2015); THCV is considered a tissue specific and dose-dependent (low dose) antagonist at CB1 receptors (high dose agonist); data further suggests THCV's ability to modulate CB2 (partial agonist), GPR-55, and Serotonin receptor sites (5-HT1A).

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.